B cell depletion in autoimmune disease (Q33361142)

26 July 2017

7 references

30 June 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

29 October 2020

B cell depletion in autoimmune disease (English)

1 reference

26 July 2017

7 references

30 June 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

29 October 2020

1 reference

27 September 2019

1 reference

12 October 2019

hemic and immune systems

1 reference

18 October 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

29 October 2020

3

David Isenberg

1 reference

26 July 2017

Claire Gorman

1

1 reference

PubMed ID

15180893

26 July 2017

Maria Leandro

series ordinal

2

1 reference

26 July 2017

2 October 2003

8 references

Arthritis Research and Therapy

26 July 2017

30 June 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

29 October 2020

8 references

26 July 2017

30 June 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

29 October 2020

5 Suppl 4

1 reference

26 July 2017

S17-21

1 reference

https://scigraph.springernature.com/pub.10.1186/ar1007

26 July 2017

0 references

cites work

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Rituximab: perspective on single agent experience, and future directions in combination trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Assessing patients with lupus: towards a drug responder index

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Use of rituximab, the new FDA-approved antibody.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

The role of antibodies to DNA in systemic lupus erythematosus--a review and introduction to an international workshop on DNA antibodies held in London, May 1996.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

CD20: a regulator of cell-cycle progression of B lymphocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

An open study of B lymphocyte depletion in systemic lupus erythematosus

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Rituximab: an insider's historical perspective.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833439

Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment

31 October 2018

1 reference

12 December 2020

Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation

1 reference

12 December 2020

Organ-specific disease provoked by systemic autoimmunity

1 reference

12 December 2020

1 reference

12 December 2020

Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

1 reference

12 December 2020

Rituximab for myasthenia gravis developing after bone marrow transplant

1 reference

12 December 2020

Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

1 reference

12 December 2020

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR1007

1 reference

PubMed ID

15180893

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference

PubMed ID

15180893